Publications
5674 Results
- Journal / Conference
- Journal of Clinical Oncology Jun 10;33(17):1910-1917
- Year
- 2015
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- PMID25940724
- PMC
- PMC4451174
- Study Number(s)
- S0927
Randomized multicenter placebo-controlled trial of omega-3-fatty acid for the control of aromatase inhibitor-induced musculoskeletal pain (S0927)
- Journal / Conference
- Cancer Prevention Research Jul;8(7):590-596
- Year
- 2015
- Research Committee(s)
- Cancer Control
- PMID
- PMID25926387
- PMC
- PMC4491033
- Study Number(s)
- SWOG-9217
Association between serum fatty acids and intraprostatic inflammation in the placebo arm of the Prostate Cancer Prevention Trial
- Journal / Conference
- Journal of Urology, Vol. 193, Issue 4, e807 [abst MP65-02]; American Urological Association (May 15-19, 2015, New Orleans), moderated poster presentation;
- Year
- 2015
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1011
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer: SWOG S1011 (NCT #01224665)
- Journal / Conference
- PLOS ONE Jun 30; 10(6):e0131106
- Year
- 2015
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID26125186
- PMC
- PMC4488332
- Study Number(s)
- S0000
Methodological considerations related to genome-wide assessments of height heritability in a large sample of african ancestry adults
- Journal / Conference
- Prostate, Sep;75(13):1403-1418
- Year
- 2015
- Research Committee(s)
- Cancer Control
- PMID
- PMID26047319
- PMC
- PMC4536102
- Study Number(s)
- SWOG-9217
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial
- Journal / Conference
- American Surgical Association (April 23-25, 2015, San Diego, CA), oral presentation, abst. 3;
- Year
- 2015
- Research Committee(s)
- Breast
- Study Number(s)
- CTSU/C40603
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant paclictaxel followed by doxorubicin and cyclophasphamide on breast conservation rates: Surgical results from CALGB 40603 (Alliance)
- Journal / Conference
- AACR 2015 Meeting (April 18-22, 2015, Philadelphia, PA), abst. 4605, poster presentation;
- Year
- 2015
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial
- Journal / Conference
- Journal of Clinical Oncology Jul 20;33(21):2384-2391
- Year
- 2015
- Research Committee(s)
- Genitourinary
- PMID
- PMID26077237
- PMC
- PMC4500832
- Study Number(s)
- CTSU/E2804
BEST: A randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma-a trial of the ECOG-ACRIN Cancer Research Group (E2804)
- Journal / Conference
- Prostate, Aug;75(11):1160-1166 2015
- Year
- 2015
- Research Committee(s)
- Cancer Control
- PMID
- PMID25893825
- PMC
- PMC4475463
- Study Number(s)
- SWOG-9217
Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial
- Journal / Conference
- American Society of Preventive Oncology (March 14-17, 2015, Birmingham, AL), poster;
- Year
- 2015
- Research Committee(s)
- Prevention, Screening, and and Surveillance